Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial

BACKGROUND: Ensartinib, a potent second-generation tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK), MET and ROS1, was evaluated in a phase I clinical trial in patients with advanced, ALK-rearranged non-small cell lung cancer (NSCLC). METHODS: Patients with advanced, ALK...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yuxiang, Pan, Hui, Liu, Yu, Zhang, Yang, Hong, Shaodong, Huang, Jianjin, Weng, Shanshan, Yang, Yunpeng, Fang, Wenfeng, Huang, Yan, Xiao, Shanshan, Wang, Tao, Ding, Lieming, Cui, Lingling, Zhang, Li, Zhao, Hongyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840022/
https://www.ncbi.nlm.nih.gov/pubmed/36647478
http://dx.doi.org/10.21037/jtd-22-1606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840022/
https://www.ncbi.nlm.nih.gov/pubmed/36647478
http://dx.doi.org/10.21037/jtd-22-1606

Ejemplares similares